# KPV: Research Overview — Peptide R Lab > A citation-anchored research summary of KPV, an anti-inflammatory tripeptide fragment of alpha-MSH studied in murine gut-inflammation models. Mechanism, findings, and an honest note on the absence of human trials. A tripeptide fragment of alpha-MSH that suppresses gut inflammation in mice — an honest chart note: every data point on this page is preclinical. ## The short version KPV (Lysine-Proline-Valine) is a linear tripeptide corresponding to the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It keeps the parent hormone's anti-inflammatory action while dropping the pigment-darkening (melanogenic) effect that comes with alpha-MSH itself. In laboratory and mouse studies, KPV dampens inflammatory signaling in gut tissue and immune cells, primarily by blocking the NF-kB and MAP-kinase pathways that drive inflammation. The chart note here is direct: **no published human clinical trial of KPV exists.** Every finding on this page comes from cell cultures or mouse models of colitis. That does not mean KPV is unsafe or ineffective in people — it means nobody has formally checked either way. KPV is sold strictly as a research chemical, carries no established human dose, and this page does not describe or imply one. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), molecular formula C16H30N4O4, corresponding to residues 11-13, the C-terminal three amino acids, of alpha-melanocyte-stimulating hormone (alpha-MSH) [13]. It is also written as Lys-Pro-Val or referred to as alpha-MSH(11-13). ## How it works KPV retains alpha-MSH's anti-inflammatory signaling while losing the pigmentary (melanogenic) action that defines alpha-MSH's better-known role in skin tanning [13]. In the gut specifically, it is taken up directly into epithelial cells through the di/tripeptide transporter PepT1 (SLC15A1), a transporter that is itself upregulated in inflamed intestinal tissue, which may concentrate KPV where it is needed most. Once inside the cell, nanomolar concentrations of KPV suppress NF-kB and MAP-kinase inflammatory signaling and reduce secretion of pro-inflammatory cytokines [9]. ## What the research shows *Mechanism and cell/mouse model.* In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV reduced NF-kB and MAP-kinase activation and cytokine secretion; orally administered KPV reduced the severity of two different induced-colitis models in mice [9]. *Colonic inflammation model.* In a separate mouse study using DSS-induced and CD45RB-hi adoptive-transfer colitis models, including mice lacking the MC1R receptor, KPV-treated animals recovered earlier, regained body weight faster, and showed reduced colonic inflammatory infiltrate and myeloperoxidase activity. Because the effect held even in MC1R-deficient mice, the researchers concluded KPV's anti-inflammatory action does not require the classical melanocortin receptor [12]. *Targeted nanodrug delivery.* A 2024 study co-assembled KPV with the immunosuppressant FK506 into a PepT1-targeted nanoparticle and tested it in mice with both acute and chronic DSS-induced colitis. The combination nanodrug improved outcomes in both colitis models beyond either agent alone, restoring tight-junction proteins and lowering inflammatory cytokines [10]. *Oral nanoparticle delivery.* A separate 2017 study built hyaluronic-acid-functionalized nanoparticles carrying KPV inside a chitosan/alginate hydrogel for oral delivery, and found this targeted formulation delivered KPV to inflamed colon tissue and reduced colitis severity more effectively than non-targeted delivery, preventing mucosal damage and lowering TNF-alpha [11]. *Comprehensive review context.* A broader review of melanocortin-derived tripeptides places KPV among several related peptides showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic, and organ-injury animal models, framing KPV specifically as an anti-inflammatory alternative to full alpha-MSH because it keeps the anti-inflammatory signal without the pigmentary one [13]. ## Reported effects, cautions & safety Unlike the other three entries in this notebook, KPV does not carry its own set of community-reported anecdotal effects in the corpus behind this page — it is rarely used or discussed as a standalone research peptide, and shows up far more often as one ingredient inside blends like [KLOW](/klow). That absence is itself worth noting honestly rather than filling in with borrowed anecdotes from other peptides. The cautions below are drawn directly from the cited literature and the honest limits of what has been studied, not from any safety-signal finding, because none exists yet for KPV specifically: - **No published human clinical trials of KPV exist.** The entire efficacy literature is in vitro and animal, chiefly mouse colitis models, so human dosing, efficacy, and safety are all unestablished [9][10][11][12]. - **KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics.** Much of the recent formulation work in the literature, the nanoparticle and hydrogel delivery studies above, exists specifically to solve the problem of keeping KPV intact long enough to act [10][11]. - **Marketing claims for gut health, skin, or general anti-inflammatory use outrun the evidence**, which remains mechanistic and preclinical rather than clinical. - **KPV should be distinguished from melanocortin agonists used for pigmentation or tanning.** Its defining feature in the literature is anti-inflammatory action *without* the pigmentary effect of its parent hormone [13]. - **KPV is sold for laboratory research use only** and is not an approved drug or dietary supplement in any major jurisdiction. ## Where it fits in the repair cascade KPV supplies the anti-inflammatory, gut-and-immune arm of this notebook's repair cascade, a counterpart to [BPC-157](/bpc-157)'s angiogenesis focus and [TB-500](/tb-500)'s cell-migration mechanism. It is also the fourth listed ingredient in [KLOW](/klow), where it is paired with BPC-157 and TB-500 plus GHK-Cu in a single research vial, though, as the KLOW page details, nothing has tested that combination directly. Read the [comparison page](/compare) to see KPV's evidence base set against the other three, including the gap this page has been careful not to paper over: it is the only entry here with zero human data of any kind. ![KPV research illustration — fine filament networks in cyan](/images/kpv.webp) --- Peptide R Lab keeps a citation-anchored bench log on tissue-repair peptides — a research chart, not a treatment plan.